Jonathan R. Davies

I'll research this attorney carefully, starting with the tracked cases to disambiguate — the case mix (Qomplx/Microsoft, SoundClear/Google, POSCO/ArcelorMittal) doesn't match the well-known life-sciences Jonathan Davies at Cooley/Norton Rose Fulbright, so I need to check whether there are multiple attorneys with this name.

Professional Summary — Jonathan R. Davies

Practice focus. Publicly documented sources describe Jonathan R. Davies, Ph.D. as a Washington, DC patent litigator concentrated in life sciences: pharmaceutical and biotechnology disputes, including Hatch-Waxman ANDA litigation, biologics disputes under the BPCIA, and pharma trade-secret cases (Norton Rose Fulbright bio; Cooley bio; Washington Business Journal, Feb. 2026). His scientific background is in molecular genetics. Disambiguation caveat: the tracked case list attributed to him spans a broader mix — including Qomplx LLC v. Microsoft Corp. (Irell & Manella), SoundClear Technologies LLC v. Google LLC (Gibson Dunn), and POSCO Co. Ltd. v. ArcelorMittal (Michael Best & Friedrich) — that does not align with his published life-sciences profile. Web searches returned no confirmation linking those specific matters to the Norton Rose Fulbright/Cooley attorney, so the tracked list may reflect a same-name practitioner; I have treated only the Cooley/Norton Rose Fulbright record as verified.

Side preference and firm context. Of his eight tracked appearances, six are defendant-side and two plaintiff-side, indicating a primarily defense-oriented practice. His verified work has been for innovator/pharma product companies and accused infringers (e.g., Liquidia, CSL Behring, Vifor, AbbVie) — not NPEs. He is currently an IP disputes partner at Norton Rose Fulbright US LLP (Washington, DC), having joined in February 2026 from Cooley LLP, where he was a partner in the life-sciences IP litigation group; earlier Hatch-Waxman matters (for AbbVie, Astellas, Eli Lilly, Forest Labs) predate his Cooley tenure, but I could not reliably source the pre-Cooley firm.

Notable matters and PTAB/IPR. Named tracked and verifiable matters include United Therapeutics Corp. v. Liquidia Technologies (Hatch-Waxman and parallel IPR, plus related trade-secret litigation in M.D.N.C.), Biofer S.p.A. v. Vifor (Injectafer), Shire ViroPharma v. CSL Behling (Haegarda), and AbbVie v. Boehringer Ingelheim (Humira, BPCIA). He has genuine PTAB/IPR experience: his biography was filed as petitioner's evidence in IPR2021-00406 (Liquidia v. United Therapeutics), and his firm bio confirms IPR representation of pharmaceutical clients. He is Chambers USA "Up and Coming" (DC IP Litigation, 2026) and a former Super Lawyers Rising Star, and he has taught Hatch-Waxman/BPCIA litigation as an adjunct at American University Washington College of Law.

Credentials. Bar: District of Columbia (2008/2009) and Maryland. Education: J.D., Ohio State University Moritz College of Law (2008); Ph.D. in molecular genetics, Ohio State; M.S., Penn State; B.A. in biology, Grove City College; Order of the Coif.